

Technology Advisory Committee D Interests Register

Topic: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

Publication Date: 05 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Will Sullivan	TAC Committee Member	Direct - Financial	<p>- Through work at his past employer, Will provided advice and support to Merck Sharp & Dohme regarding pembrolizumab for peri-adjuvant non-small-cell lung cancer. This engagement ended in October 2023.</p> <p>- Through work at his past employer, Will also provided advice and support to the same company regarding pembrolizumab for locally advanced, unresectable esophagael/gastroesophagael junction cancer. This engagement ended on 6 November 2023, when Will's employment at Delta Hat ended.</p> <p>No comparator company conflicts to declare for the past 12 months.</p>	10/07/2024 03/10/2024	It was agreed that Dr Sullivan's declaration would not prevent them from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Bradley	TAC Committee Member	Direct - Financial	Dr Bradley hold shares in the company AstraZeneca. Dr Bradley's conflict will mean he is not participating in this topic's discussion.	11/07/2024 03/10/2024	It was agreed that Dr Bradley's declaration would prevent them from participating in discussions on this appraisal.
Mary O'Brien	Clinical Expert	Direct - Financial	Book, Fast Facts in lung (finance to lung unit) 2017-2022 and ongoing) 2 editions Advisory boards with: <ul style="list-style-type: none"> • AZ x 2019, 2023 • Puma x 2 2020 • Sanofi x once 2018 • Amgen x 2 2021 • BMS x 2 2015 • MSD x 5 2017 and ongoing • Iteos x 3 plus lecture 2021-ongoing • Janssen 2023. ASCO funding MSD 2022. IDMC – Pharmamar 2023.	07/08/2024	It was agreed that Mary's declaration would not prevent them from providing expert advice to the committee.
Toby Talbot	Clinical Expert	Direct - Financial	<ul style="list-style-type: none"> • Advisory board activity with MSD and speaker fees: 	07/08/2024	It was agreed that Toby's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> ○ Clinical expert at MSD UK NSCLC advisory board held on 1st December 2023 ○ Speaker at MSD symposium at BTOG annual meeting held on 26th April 2023 		providing expert advice to the committee.
Professor David Meads	TAC Committee Member	Professional	University of Leeds (Professor Meads' employer) has received funding from BMS for research in an unrelated area.	10/09/2024	It was agreed that Professor Meads' declaration would not prevent them from participating in discussions on this appraisal.